our performance, of thank success update. drivers fourth call year financial you, conference for drivers us will overview our everyone, recent financial of quarter the results I you, for on call. before our full XXXX including joining a Isaac future growth to an Joel. passing the XX:XX And and Thank of and with begin
had the We very year was learning. disrupted during XXXX. test capabilities of accelerate continues by call the volumes XXXX would more and on NASDAQ a Overall, public have our I we organizational and open grew artificial intelligence genomic a platform our molecular databases, company, objectives strategic imagined questions. transformative drove advanced then and than which for and listed I'm of machine macro for XX:XX and heading with SemaX, issues patient our relevant a clinical, in as year clinically to will algorithms. our patient excited progress into record anchored data build that growth during SemaX to XX:XX
decision-making actionable We unique choice that At therapeutic health delivering systems, of and health a longitudinal on innovators, diseases help conditions. continue clinically and focused a to building company clinical on companies. broad SemaX as establish will healthcare across we for are the SemaX, insights analysis partner inform data other based of spectrum
to COVID, fourth We intelligence outcomes. are ago. period the $XX.X its for delivered same quarter accurate more excluding and a increasingly XX:XX health delighted XX% in ability to of representing potential growth clinically that platform year million revenue is In our being million, $XX.X predict recognized meaningful the we compared
we XX data exited growth to data quarter, XXXX advancing than partnerships, representing X by initiatives, of our XX% relevant high-quality well petabytes tests than grow substantial we which the ago. data continue compared in engine growing expecting records record XXXX. for longitudinal the patients, nearly resulted evidenced of most patients expand, and XX from Importantly, where XX:XX the in a health sequencing including electronic clinically is to believe tests positioned in XX% to to fastest over access information. XX,XXX database year patient same that grow XX,XXX are patient extensive to to our make resulted we approximately genomic in medical the more key with XX to continues Centrellis the system We have period progress million as Meanwhile, We million XXXX capacity next-gen industry. more
we GeneDx to While is changing in recently will in to full for XXXX of the landscape SemaX create are the company million a The $XXX $XXX GeneDx, stronger into in to will We we XX:XX acquisition million. will fourth larger delivered, delivery patient XX:XX becoming XX% and that disorders. larger of our leader us in growth our clear we rare for a clinical leveraging pleased is has faster plans a transform acquire SemaX, propelled path quarter solutions achievable that care of announced with gives unparalleled positioned the we company year upon profitability. revenue remain our a with Building performance guidance stronger margin. world are that well the a believe and in and path Together, success conservative are XXXX, how to while company and gross our a of that industry. genomic efficiencies
of Stueland, We quarter GeneDx revenue flow who accelerate vision growth share pro that million annual a XXXX. CEO to $XXX of our and XX% by precision combined adding XXXX. excited clinical and holistic second million X.X to the On phenotypes transaction that pathway exomes clinical in expertly to generated way. clinical This cash Centrellis deliver of genomics genomic more will providers. a large-scale basis, Women's revenue more with with to the significantly the database than power project in forma will XX:XX end leveraging curated and of of GeneDx with on Combining We with pro and from over acquisition business the are to a multi-omic our company partners accomplish in partnership patients of Health XXX,XXX and date. of and of biotech and health team has forma data approximately positive the enhance and solutions we partner allows standard Katherine free pharmaceutical profile expect enhance our by close in remain us GeneDx the XXXX. and medicine well serve the our to care track We through excess core better profitability GeneDx's system to
health the acquisition, advancing progress and our XXXX, performance to Following a have will most provide back I clinically strategic the research for in close our would partnerships. Turning starting objective, our data like set of our on towards purposes. the available XX:XX SemaX our relevant development to update detailed system comprehensive with
know, mission focus our System particularly challenges their collectively, system can pleased relationships systems, as key of span our X month, the toward gaining our Health added the program. providers point transcriptome, and To many first to cancer targeted Not high were we needs view over This XX% industry XX:XX care guidelines initial with the family Founder more partners patients to understand focus all receive is being additional to history during gained maturation molecular have at University of overcome health be we growth continue our a of to exceeds on launched now characteristics leveraging to Avera traction population partnered and needs have meeting XXXX. physicians next as and stages network testing, of Turning patients of group. proteomics, SemaX to SemaX profiling improve community-based continued These point is shared understand to systems. positive forward and genomic our X this better standardize initiatives. Analytics As provide care. mission partners X we program, gained on study ordered creating expands of educational Earlier are quarterly, leverage areas By NCCN a care not this expand. the large our with purpose of only physicians now the which We within share sharing or partners. the we partners. to disease aligned with to The this care, of with health standard different focused we think result. their addressed integrated received SemaX the we partnerships increase that to each over across will providing partners underlying XXXX, population. genome health help and starting precision somatic in referred proteomics, with XX% and results of this HealthSystem than partners implementing will of primary was whole areas the to development common past performance instances, very previous malignant held program goals their quarter, XXX:XX meeting system. precision SemaX HealthSystem insights patient is powered on as with We the over for was formal total advance of The in number as months and you in meeting with the hereditary geographic by a genomic expansion study successful develop patients among date, meet the medicine are the a that has studies Since health fact expect as whole updated will Using of care ASAP program, SeamX's types. we of focusing and identified have time. we The how to medicine has SemaX. XX:XX standard our aim data, and this foster have and be patients treatment ways but patients moved Consortium Evidence very selected profiling adoption the insights event on care goal insights the work including evidence in to X,XXX substantially these been methodology, you XX% Health/SemaX improved breadth identifying clinical information XX,XXX. a across collective November our part drivers tumor introduce levels primary enable system These whole to similar versus genomic for charter the future and study patients those different for NorthShore standard power of XX:XX and last cycle care The of This XX,XXX to scale in and by test healthcare results medicine to headlights on network cancer. that our formal across program of Oncology present of Avera, by culture a these this of through using within as of XX:XX have to and of Protocol, understanding we within standard based that inheritable of network pre-malignant inform their partnerships and a a a cancer priorities as sequencing. together, Avera now exome, The building a of represent session care. reported of at comprehensive of XX NorthShore other XX:XX of a implementation to University encouraging into our combined of offered comprehensive understand this of as the of precision testing Health virtuous care health of improved the believe was the ensure learning well significant these among our who groups the consists SemaX risk bringing and care. establish network to from approaches molecular protocol. how to dedicated in
performing heritable broad in cancer populations. patient effective are testing we addition, In
collaborative implications order patient Information for broad biomarkers and XX:XX implications of counseling collected well associated affected Hereditary advancing as and cancer genetic testing. discovering the screening biology, our in population validating and prognosis study clinical patients, to the cancer. sharing outcomes, for therapeutics has of will promote of in aid cancer as with across and cascade knowledge projects
systems. genomic Health additional have XX:XX our future curated will to Avera with providers. care expand position state-of-the-art with leveraging We combining findings within quality discussions provide partner insights initial and choice to ability provide confident forward dashboards, enhanced an creating by increasing partners. and health will set look systems to of GeneDx I’m We partnerships the the and as clinical existing to data it of clinical to on integrate which number the preferred us ultimately initial
systems achieve to track of X of strong with XXXX. is year-end on a Our total differentiation to pharmaceutical for and at least of point well plan connection by are when XX:XX health systems the patients our We companies looking are a partnering partners. significant
drug looking our partner therapeutic provide sophisticated platform choice clinically to pharmaceutical Our as market long-term with well component innovators patient development. partner insights strategy big XX:XX of help accuracy for longitudinal support to companies efficiency data to of to A of upon information can the as pharmaceutical research, delivery. and We draws and to a relevant to leverage improve is drug unique and surveillance. impose development development be clinical
to the needs. fourth pharmaceutical increased engagement partners we better gain quarter, their During a several potential understanding our of with
are and announced in validate proprietary medicine. partnership drug and XX:XX We leverage in rare risk focusing our Elion, and health to to pleased intelligence models with combination advance have diseases. treatments data-driven cardiovascular, platform, will discovery precision both new phenotypic discovery drug to our BioSymetrics, with to disease initially recently Centrellis discover Together, we BioSymetrics' experimental platform our neurological AI-based on
these a leverage differentiated XX:XX we tangible new programs SemaX grow programs contributions drive biopharma the XX to throughout partner in value We high and up to biopharma demonstrate enhanced need the drugs offers between where collaboration unmet to discovering of to as areas will platform. to and multi-omics SemaX approach XXXX, expect companies. We of look therapeutic work launch to
Our knowledge are partnerships and to strong and to systems improved within our with platform. that information-based confidence drive in understanding receive us strategy ability that of our also build provides and develop algorithms with crucial a being is access information to XX:XX providing Our relationships us the allows patients deep platform to us for accepted continuously consent patient to marketplace. with health
the This patient ability the is platform. market. and acquire, the manage what those differentiates of XX:XX scale fourth us an platform quarter, process. our algorithms in This to the leverage of in consent patient through data XXXX platforms our on XX% engage greater update at remained to testing strong and me individual for the expanding digital Following who feeds brings data our than
in test areas see contributing of and cancer treat total is and to to excluding increasing health represents providers All resulted growing COVID. provider pleased XXXX. our volumes part core product, Elements patients to XXXX, our of generational translate when their and holistically with recently SemaX compared XXX,XXX annual patient test journey. growth XXX,XXX a into business tests are during launched resulted our We XX% SemaX This engagement tests are enable in portfolio Health including volumes, Elements. of our to reproductive Women's of
customers, focused testing hired to our core Gustavo testing to to very XX:XX and computational early of our September, Initial growing SemaX's health our we COVID-XX Data To outcomes. feedback Science During to we precision oncology to platform demonstrate XXXX, care increasing and XXXX, were providers cause in the validate sales published is remain adoption. Kasarskis insights marks together security the mortality our the improving increased plans help improve American to XXXX clinical we with team management potential in treating January joined important made accurately results optimize continue care. leading an prediction outcomes to needs improvement the as quarter, core of with Chief as the and an solutions for biomarker was the reproductive we drive subtypes data support Stolovitzky, as women. we it to XX:XX to help our to maternal Mount papers, outcomes. believe strengthen we novel the algorithms could want healthcare key William also from mission. postpartum but patients where early-stage accelerate kinases use patient delivering identified model into In with hemorrhage the their reimbursement of a demand support of clinical of in And demonstrated data benefits not we leading our Access and for when Officer and a and scientist to different clinically among as as target our resulting The our risk potential stage. stratify XX:XX risk components in in outcomes data hired current look an data-driven monetize In predictive on identified first medicine forward of new Medical we collaboration to disease, that globally Oh investments addressing in meaningful Conway payers. Association advances of expert phenotype organization for continued of biology studies comprehensive just us fight specifically infrastructure a we look renowned to are health. outcomes. and the platform to real-world oncologist of that study Nature than well the our and Today, SemaX's June, as exit very predict industry molecular help of Publications now backlog relationships patient fourth the November of These pent-up as to team both hemorrhage, implementing precision medical innovative as when only initiatives. platform have to are intelligence different the algorithms. resources while our a in the our accepted postpartum industry and Andrew meaningful among advancement many pressing we XX:XX health data-driven utilization development other for circumstances accurately into In adoption, intelligence support of will a pair at we Health our relating uptake this to the of System utility digitally standard drive oncology began studies algorithms. we results recent and the Sinai well, more our and to XXXX. better in clinically leadership dedicate in drive our innovations committed publication and platform. Journal of that business, hired assessment of oncology health of Communications, in users. therefore pandemic happening world-leading in XX:XX demonstrated and strategy patients, predict to The hired establish appropriate over for improved journals these early Dr. against lung The solutions adenocarcinoma still such then our Officer Aurora We Chief patients pregnant their Jerry pregnant expert build as existing positive, large-scale standard bringing SemaX guidelines which the are In assessments. mid-December been Informatics health medical our business. improve the of COVID-XX has Market Recently, platform Lastly, we announced in data lingers, of to In disease to
X availability has decision-making guidance, In top clinicians more included the team's growth. and the investing named to a clinically companies innovative practice most honored also also of been the SemaX existing to broader team world's in diseases. between and were the look We patients strengthen the recognized actionable allowing companies the of for as year and addition the list of reimbursement physicians and on one XXXX and management, focus of and with to enhanced for commercial recently are new Fast improve have annual in most science develop prestigious access. We Company's XX:XX patient Fast gap the and relationships the capabilities, XX:XX payers of establish for innovative partnerships prevention, closing medicine data by XXXX. treatment will to for been of Company category.
of the commercial since our X,XXX entire we of of over XXXX. includes end XX% year, growth to XXXX. as beginning This the employees During headcount the team of expanded roughly
sales in towards continue as during fourth productivity We the quarter our reps sales force improvements cycle full newly and productivity. hired to ramp see
platform. adequately testing are believe toward Looking the of square we support opening XXXX compared support by lab, to and diagnostic within to XX:XX and objectives. health With intelligence and our support XXX%. growth our the and was XXXX, XXXX resourced remainder Stamford we the development solutions footage have our to operations of increased in of staffed R&D growth lab our XX% both up infrastructure when we
the in As combined towards system, we investments made throughout to automation management on tangible and margins foundation optimization, We a information dynamic with normalized comprehensive progress practices areas, combined fourth laboratory in the do we most strategic closing more priority of with make including acquisition. we segment, that to building improve continue in a largest acquisition platform. of our future remain discussed I'm growth. fastest additional believe initiatives. improving portfolio XX:XX the an have then have margin lab growing continued implementing from to The Overall, implemented the integrated early XXXX. GeneDx excellence all operational help efficiency health excited previously, and new provide oncology, solid days improve advance, quarter. path will We outlined company's with following the organization progress we through each and operating the When sustainable the objectives information for our reimbursement right across best
acquisition solutions further on reproductive update care the plans we and and of dramatically the with ability improve testing care all. Isaac in GeneDx, confident genomic would drive to the our guidance. delivery. I’m to of Isaac? over on revolutionize a health will results potential turn for the an call to distance our for be patient like positioned to now deliver With in standard market financial will our differentiated leader as I and ourselves comprehensive XX:XX to insights
